The metabolism and drug–drug interaction potential of the selective prostacyclin receptor agonist selexipag

References

• Agarwal S, Arya V, Zhang L. (2013). Review of P-gp inhibition data in recently approved new drug applications: utility of the proposed [I(1)]/IC(50) and [I(2)]/IC(50) criteria in the P-gp decision tree. J Clin Pharmacol 53:228–33
   PubMed Web of Science ®Google Scholar
• Baldoni D, Bruderer S, Muhsen N, et al. (2015). Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study. Int J Clin Pharmacol Ther 53:788–98
   PubMed Web of Science ®Google Scholar
• Bruderer S, Hurst N, Kaufmann P, et al. (2014). Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. Pharmacology 94:148–56
   PubMed Web of Science ®Google Scholar
• Bruderer S, Okubo K, Mukai H, et al. (2016). Investigation of potential pharmacodynamic and pharmacokinetic interactions between selexipag and warfarin in healthy male subjects. Clin Ther 38:1228–36
   PubMed Web of Science ®Google Scholar
• Clapp LH, Gurung R. (2015). The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: role of membrane versus nuclear receptors. Prostaglandins Other Lipid Mediat 120:56–71
   PubMed Web of Science ®Google Scholar
• Duggan ST, Keam SJ, Burness CB. Selexipag (2017). Selexipag: a review in pulmonary arterial hypertension. Am J Cardiovasc Drugs 17:73–80
   PubMed Web of Science ®Google Scholar
• EMA. European medicines agency. Committee for Human Medicinal Products (CHMP) (2012). Guideline on the Investigation of Drug Interactions, CPMP/EWP/560/Rev.1 Corr. 2. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf
   Google Scholar
• FDA. United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2012). Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Available at: https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf
   Google Scholar
• Fenner KS, Troutman MD, Kempshall S, et al. (2009). Drug-drug interactions mediated through P-glycoprotein: Clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 85:173–81
   PubMed Web of Science ®Google Scholar
• Galiè N, Corris PA, Frost A, et al. (2013). Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 62 (25 Suppl):D60–72. 12
   Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery JL, et al. (2015). ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37:67–119
   PubMed Web of Science ®Google Scholar
• Gatfield J, Menyhart K, Wanner D, et al. (2017). The selexipag active metabolite ACT-333679 displays strong anti-contractile and anti-remodeling effects, but low β-arrestin recruitment and desensitization potential. J Pharm Exp Therap. 362:186–99
   PubMed Web of Science ®Google Scholar
• Hardin EA, Chin KM. (2016). Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy. Drug Des Develop Ther 10:3747–54
   PubMed Web of Science ®Google Scholar
• Hoch M, Darpo B, Remenova T, et al. (2015). A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist. Drug Des Devel Ther 9:175–85
   PubMed Web of Science ®Google Scholar
• Humbert M, Ghofrani HA. (2016). The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax 71:73–83
   PubMed Web of Science ®Google Scholar
• Juif PE, Boehler M, Donazzolo Y, et al. (2017). A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects. Eur J Clin Pharmacol. 73:1121–8
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Hurst N, Astruc B, et al. (2017). Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist. Eur J Clin Pharmacol 73:151–6
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Okubo K, Sidharta PN, et al. (2012). Investigation of the absorption, metabolism, and excretion of 14C-selexipag following oral administration to healthy male subjects. Clin Pharmacol Ther 91(suppl. 1):S85
   Web of Science ®Google Scholar
• Li B, Sedlacek M, Manoharan I, et al. (2005). Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70:1673–84
   PubMed Web of Science ®Google Scholar
• Sardana M, Moll M, Farber HW. (2016). Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension. Expert Opin Drug Metab Toxicol 12:1513–20
   PubMed Web of Science ®Google Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. (2013). Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62:D34–41
   PubMed Web of Science ®Google Scholar
• Taichman DB, Ornelas J, Chung L, et al. (2014). Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest 146:449–75
   PubMed Web of Science ®Google Scholar
• Tuder RM, Cool CD, Geraci MW, et al. (1999). Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159:1925–32
   PubMed Web of Science ®Google Scholar
• Yang D, Pearce RE, Wang X, et al. (2009). Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol 77:238–47
   PubMed Web of Science ®Google Scholar